Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer

Fettke, Heidi; Kwan, Edmond M.; Docanto, Maria; Bukczynska, Patricia; Ng, Nicole; Graham, Lisa; Mahon, Kate; Hauser, Christine; Tan, Winston; Wang, Xiaohong; Zhao, Zhixin; Zheng, Tiantian; Zhou, Kemin; Du, Pan; Yu, Jianjun; Huang, Yong; Jia, Shidong; Kohli, Manish; Horvath, Lisa G.; Azad, Arun

doi:10.1016/j.eururo.2020.03.044

Cited by 51 publications

(52 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Future applications may also benefit from incorporating measurements from other nucleic acids entirely like cfDNA or other molecules like proteins and metabolites as has recently proven informative for prostate cancer (50) and PTB prediction (51), respectively. One recent report that examined both cfDNA methylation and cfRNA measurements for pregnancyrelated complications found that in a small discovery cohort, placental-specific cfDNA increased prior to the subsequent development of gestational diabetes and that other cfRNA changes preceded preeclampsia (36).…”

Section: Future Applicationsmentioning

confidence: 99%

Investigating Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood During Gestation

et al. 2020

View full text Add to dashboard Cite

In recent years, there have been major advances in the application of non-invasive techniques to predict pregnancy-related complications, for example by measuring cell-free RNA (cfRNA) in maternal blood. In contrast to cell-free DNA (cfDNA), which is already in clinical use to diagnose fetal aneuploidy, circulating RNA levels can correspond with tissue-specific gene expression and provide a snapshot of prenatal health across gestation. Here, we review the physiologic origins of cfRNA and its novel applications and corresponding challenges to monitor fetal and maternal health and predict pregnancy-related complications.

show abstract

Section: Future Applicationsmentioning

confidence: 99%

Investigating Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood During Gestation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Circulating GRHL2 expression may reflect a tumour's increased reliance on the AR pathway as a primary method of growth signalling. Whilst theoretically this may render such tumours more susceptible to AR directed therapies, the presence of AR gain/amplification in plasma circulating tumour DNA and circulating tumour RNA (ctDNA/ ctRNA) next-generation sequencing assays has consistently been shown to be a negative predictive biomarker for response to both abiraterone acetate and enzalutamide (11,(33)(34)(35)(36)(37). Similarly, detectable GRHL2 mRNA in the mHSPC cohort could suggest greater dependency on ARmediated proliferation that is incompletely suppressed with LHRH analogue monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

Kwan¹,

Fettke²,

Crumbaker³

et al. 2021

Transl Androl Urol

Self Cite

View full text Add to dashboard Cite

“…AR-V1, AR-V2, AR-V3, AR-V5, AR-V7, AR-V9 and AR-45 AR gain and cumulative number of AR aberrations including AR-V7 and AR-V9 are associated with shorter PFS and OS. [42] AR-V7 and AR-V9 AR-V9 in tissue is associated with resistance to ABI. [50] Abbreviations: ABI-abiraterone acetate, ENZ-enzalutamide, PFS-progression-free survival, OS-overall survival, RISH-RNA in situ hybridization, BCR-biochemical recurrence, BAT-bipolar androgen therapy.…”

Section: Ar-v7mentioning

confidence: 96%

AR Splicing Variants and Resistance to AR Targeting Agents

Kanayama

Luo

et al. 2021

Cancers

View full text Add to dashboard Cite

Over the past decade, advances in prostate cancer research have led to discovery and development of novel biomarkers and effective treatments. As treatment options diversify, it is critical to further develop and use optimal biomarkers for the purpose of maximizing treatment benefit and minimizing unwanted adverse effects. Because most treatments for prostate cancer target androgen receptor (AR) signaling, aberrations affecting this drug target are likely to emerge following the development of castration-resistant prostate cancer (CRPC), and it is conceivable that such aberrations may play a role in drug resistance. Among the many AR aberrations, we and others have been studying androgen receptor splice variants (AR-Vs), especially AR-V7, and have conducted preclinical and clinical studies to develop and validate the clinical utility of AR-V7 as a prognostic and potential predictive biomarker. In this review, we first describe mechanisms of AR-V generation, regulation and their functions from a molecular perspective. We then discuss AR-Vs from a clinical perspective, focusing on the significance of AR-Vs detected in different types of human specimens and AR-Vs as potential therapeutic targets.

show abstract

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer

Cited by 51 publications

References 30 publications

Investigating Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood During Gestation

Investigating Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood During Gestation

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

AR Splicing Variants and Resistance to AR Targeting Agents

Contact Info

Product

Resources

About